AFFiRiS develops first-in-class antigen specific vaccines for the prevention and treatment of chronic illnesses. Our proprietary AFFITOME®-Technology delivers peptides that are optimized to mimic a target specific epitope, thereby inducing an antibody response that is cross-reactive to the original target. Our indications include Neurodegenerative illnesses such as Parkinson's disease, MSA and Huntington's disease, Cardiometabolic illnesses such as Atherosclerosis and Diabetes Type II and Allergic illnesses such as Atopic dermatitis, Allergic rhinitis and Asthma.